Showing results (131-140 of 623) with videos related to
Sort By:
Pageof 63
Molecular Pharmaceutics|June 29, 2026
Done EAZY: An Automated Procedure for 89Zr-Radiolabeling and Size-Exclusion Chromatography Purification of Nanoliposomal Anticancer TherapeuticsJustin Dubbert, Falk Kunkel, Thomas Mühlenberg, et al.Oncology Research and Treatment|June 8, 2021
[18F]-Fluorodeoxyglucose Positron Emission Tomography/CT to Assess the Early Metabolic Response in Patients with Hormone Receptor-Positive HER2-Negative Metastasized Breast Cancer Treated with Cyclin-Dependent 4/6 Kinase InhibitorsRobert Seifert, Alina Küper, Mitra Tewes, et al.Oncotarget|October 4, 2014
18 FDG-PET/CT for prognostic stratification of patients with multiple myeloma relapse after stem cell transplantationConstantin Lapa, Katharina Lückerath, Uwe Malzahn, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 23, 2022
Radioiodine Ablation of Thyroid Remnants in Patients with Graves' OrbitopathyMichael Oeverhaus, Jana Koenen, Nikolaos Bechrakis, et al.Endocrine|January 2, 2019
Thyroid stunning in radioiodine-131 therapy of benign thyroid diseasesChristian Happel, Wolfgang Tilman Kranert, Hanns Ackermann, et al.European Journal of Nuclear Medicine and Molecular Imaging|March 7, 2021
Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a reviewReyhaneh Manafi-Farid, Sara Harsini, Bahare Saidi, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 2, 2023
Molecular Imaging Biomarkers in Cardiooncology: A View on Established Technologies and Future PerspectivesDavid Kersting, Ilektra-Antonia Mavroeidi, Stephan Settelmeier, et al.Theranostics|July 21, 2020
Analysis of PSMA expression and outcome in patients with advanced Prostate Cancer receiving 177Lu-PSMA-617 Radioligand TherapyRobert Seifert, Konstantin Seitzer, Ken Herrmann, et al.EJNMMI Research|May 16, 2015
Influence of the amount of co-infused amino acids on post-therapeutic potassium levels in peptide receptor radionuclide therapyConstantin Lapa, Rudolf A Werner, Christina Bluemel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomyHeiko Schöder, Ken Herrmann, Mithat Gönen, et al.Pageof 63